BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for endoglycosidase [epc]. First approved in 2019.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCEPTIN HYLECTA is a subcutaneous formulation of trastuzumab combined with hyaluronidase enzyme, designed to treat HER2-positive breast cancer. It works by antagonizing HER2/Neu receptors on cancer cells, blocking growth signaling pathways. The hyaluronidase component enables rapid subcutaneous delivery, reducing infusion time compared to intravenous alternatives.
$514KPart D
PeakThe product is at peak lifecycle stage with modest Part D spending, indicating a stable but niche market position within breast cancer treatment; commercial teams are likely focused on optimization and market penetration rather than launch activities.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers
Started Feb 2026
150 enrolled
Healthy Male Participants
Career Relevance
Working on HERCEPTIN HYLECTA as a Roche-sponsored product offers exposure to premium oncology commercialization and the monoclonal antibody therapeutic class within a peak-lifecycle franchise. Career growth is more likely in market access, medical affairs, and oncology-specialist sales than in launch-phase roles.
Company
Worked on HERCEPTIN HYLECTA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.